中性粒细胞/淋巴细胞比值在转移性结直肠癌中的预后与预测作用:GONO TRIBE研究回顾性分析
该研究基于TRIBE III期试验中413例不可切除、既往未治疗的转移性结直肠癌患者,评估基线中性粒细胞/淋巴细胞比值(NLR)的预后与预测价值。以NLR=3为界,高NLR患者无进展生存期(PFS)和总生存期(OS)均更差,多变量模型中NLR仅与OS独立相关;NLR与治疗组之间无交互作用,三药联合方案的获益不依赖基线NLR。
要点
- 基线NLR≥3的转移性结直肠癌患者预后更差,尤其体现在总生存期。
- NLR与治疗组无交互作用,FOLFOXIRI较FOLFIRI联合贝伐珠单抗的获益不依赖基线NLR。
- NLR可作为一线化疗联合贝伐珠单抗治疗患者的预后分层指标。
核心结论
- 本研究证实NLR在贝伐珠单抗联合化疗一线治疗的转移性结直肠癌患者中具有预后作用,高NLR患者预后更差。
- 三药联合方案(FOLFOXIRI)相对于两药方案的优势不依赖基线NLR。
研究设计与样本
- TRIBE试验为多中心III期随机试验,将不可切除且既往未治疗的转移性结直肠癌患者随机分配至FOLFOXIRI或FOLFIRI联合贝伐珠单抗。
- 本研究为TRIBE研究的回顾性分析,基线NLR可获取者共413例。
- 主要分析以NLR=3为界分为低NLR(<3)与高NLR(≥3),次要分析按三分位数将NLR作为三水平有序变量处理。
主要发现
- 单因素分析(多重插补后)中,高NLR患者较低NLR患者PFS显著更短(HR 1.27,95%CI 1.05-1.55,P=0.017)、OS显著更短(HR 1.56,95%CI 1.25-1.95,P<0.001)。
- 多变量模型中NLR与OS仍显著相关(HR 1.44,95%CI 1.14-1.82,P=0.014),但与PFS无显著相关(HR 1.18,95%CI 0.95-1.46,P=0.375)。
- 治疗组与NLR在PFS(交互P=0.536)和OS(交互P=0.831)方面均无交互效应。
- 低NLR(HR 0.84,95%CI 0.64-1.08)与高NLR(HR 0.73,95%CI 0.54-0.97)患者的PFS获益相似;OS结果一致(低NLR HR 0.83,95%CI 0.62-1.12;高NLR HR 0.82,95%CI 0.59-1.12)。
关键数值与推荐
- NLR定义为绝对中性粒细胞计数除以绝对淋巴细胞计数。
- 主要分析采用NLR=3作为低(<3)与高(≥3)的界值;次要分析按三分位数分布将NLR作为三水平有序变量。
临床怎么用
- 对拟接受一线化疗联合贝伐珠单抗的转移性结直肠癌患者,可用基线NLR(界值3)辅助预后分层。
- 高NLR提示预后较差,但不应据此排除三药联合方案,因其获益与基线NLR无关。
局限性
- 本研究为TRIBE试验的回顾性分析。
- 基线NLR仅413例可获取,且分析中采用了多重插补。
- 原文摘要未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neutrophil/lymphocyte ratio (NLR), defined as absolute neutrophils count divided by absolute lymphocytes count, has been reported as poor prognostic factor in several neoplastic diseases but only a few data are available about unresectable metastatic colorectal cancer (mCRC) patients (pts). The aim of our study was to evaluate the prognostic and predictive role of NLR in the TRIBE trial. PATIENTS AND METHODS: Pts enrolled in TRIBE trial were included. TRIBE is a multicentre phase III trial randomizing unresectable and previously untreated mCRC pts to receive FOLFOXIRI or FOLFIRI plus bevacizumab. A cut-off value of 3 was adopted to discriminate pts with low (NLR < 3) versus high (NLR ≥ 3) NLR, as primary analysis. As secondary analysis, NLR was treated as an ordinal variable with three levels based on terciles distribution. RESULTS: NLR at baseline was available for 413 patients. After multiple imputation at univariate analysis, patients with high NLR had significantly shorter progression-free survival (PFS) [hazard ratio (HR) 1.27 (95% CI 1.05-1.55), P = 0.017] and overall survival (OS) [HR 1.56 (95% CI 1.25-1.95), P < 0.001] than patients with low NLR. In the multivariable model, NLR retained a significant association with OS [HR 1.44 (95% CI 1.14-1.82), P = 0.014] but not with PFS [HR 1.18 (95% CI 0.95-1.46), P = 0.375]. No interaction effect between treatment arm and NLR was evident in terms of PFS (P for interaction = 0.536) or OS (P for interaction = 0.831). Patients with low [HR 0.84 (95% CI 0.64-1.08)] and high [HR 0.73 (95% CI 0.54-0.97)] NLR achieved similar PFS benefit from the triplet and consistent results were obtained in terms of OS [HR 0.83 (95% CI 0.62-1.12) for low NLR; HR 0.82 (95% CI 0.59-1.12) for high NLR]. CONCLUSION: This study confirmed the prognostic role of NLR in mCRC pts treated with bevacizumab plus chemotherapy in the first line, showing the worse prognosis of pts with high NLR. The advantage of the triplet is independent of NLR at baseline.
引用
- Dell'Aquila E, Cremolini C, Zeppola T, et al. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. Ann Oncol. 2018. PMID: 29324972. doi:10.1093/annonc/mdy004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。